Want to join the conversation?
$LMT lifted its 2016 net sales guidance to range of $49.6-51.1Bil from previous forecast of $49.5-51Bil and its 2016 EPS outlook to range of $11.5-11.8 from prior estimate of $11.45-11.75. $LMT raised its operating profit guidance to range of $5.625-5.775Bil from previous estimate of $5.6-5.75Bil.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.